Surrozen (SRZN) Change in Accured Expenses (2020 - 2026)
Surrozen (SRZN) posted quarterly Change in Accured Expenses of -$1.2 million for Q1 2026, up 2.51% year-over-year from -$1.1 million in Q1 2025, and down 139.6% quarter-over-quarter from $2.9 million in Q4 2025.
Surrozen (SRZN) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Surrozen's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 2.51% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $2.5 million (up 152.54% YoY), while the FY2025 annual figure was $2.5 million, up 137.03% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.2 million, down from $2.9 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.9 million in Q4 2025, with the low at -$3.8 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is $178000.0 (2023), against an average of -$113882.4.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses sank 310.11% in 2022, then soared 810.81% in 2024.
- Surrozen's Change in Accured Expenses stood at $651000.0 in 2022, then tumbled by 72.66% to $178000.0 in 2023, then surged by 385.39% to $864000.0 in 2024, then jumped by 239.93% to $2.9 million in 2025, then plunged by 139.6% to -$1.2 million in 2026.
- Business Quant data shows SRZN's Change in Accured Expenses at -$1.2 million in Q1 2026, $2.9 million in Q4 2025, and $555000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -799,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -799,000.00 |
| Jun 30, 2026 | -799,000.00 |
| Mar 31, 2026 | -1.16 Mn |
| Mar 31, 2026 | -1.16 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 555,000.00 |
| Sep 30, 2025 | 555,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | -1.19 Mn |
| Mar 31, 2025 | -1.19 Mn |
| Dec 31, 2024 | 864,000.00 |
| Dec 31, 2024 | 864,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Jun 30, 2024 | 658,000.00 |
| Jun 30, 2024 | 658,000.00 |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |